Advertisement

Topics

A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies

2010-07-15 17:00:00 | BioPortfolio

Summary

The main objectives of this study are to evaluate the side effects of MKC-1 and to determine a safe dose of MKC-1 for future studies in patients with hematological malignancies

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Hematological Malignancies

Intervention

MKC-1

Location

Princess Margaret Hospital
Toronto
Canada

Status

Completed

Source

EntreMed

Results (where available)

View Results

Links

Published on BioPortfolio: 2010-07-15T17:00:00-0400

Clinical Trials [603 Associated Clinical Trials listed on BioPortfolio]

Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells

The investigators have previously shown the absence of toxicity of Treg-depleted-DLI and the possibility to triggering alloreactivity (GVHD/GVT) in relapsing patients dealing with hematolo...

MS Detection of Somatic Mutations in Hematological Malignancies

Detection of somatic mutations in hematological malignancies is now routinely assessed by NGS sequencing. This powerful approach is nevertheless time consuming and its costs represent limi...

Evolution of Thromboelastography During Tranexamic Acid Treatment

Patients with hematological malignancies are at increased risk of bleeding, especially during intensive chemotherapy. The aim of this study is to compare by thromboelastography changes dur...

Intrabone Infusion of Cord Blood in Adults With Hematological Malignancies

The purpose of this study is to evaluate the engraftment of donor hemopoiesis (proportion of transplanted patients with successful engraftment at day +42) in adult patients affected by hig...

Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies

The purpose of this trial is to determine safety and efficacy of 16 weeks treatment with thymosin alpha 1 given at 1.6 mg dose once daily by subcutaneous injection in adult patients with h...

PubMed Articles [1137 Associated PubMed Articles listed on BioPortfolio]

Research Advances on Role of Extracellular Vesicles in the Bone Marrow Microenvironment of Patients with Hematological Malignancies--Review.

Bone marrow (BM) microenvironment appears to play an important role in the pathogenesis of hematological malignancies. Apart from soluble factors and direct cell-cell contact, the extracellular vesicl...

Nested polymerase chain reaction with specific primers for Mucorales in the serum of patients with hematological malignancies.

Mucormycosis is an opportunistic infection occurring in immunocompromised hosts with hematological malignancies. Mortality due to mucormycosis in patients with hematological malignancy is high. Howeve...

Fungemia in hematological malignancies: SEIFEM-2015 survey.

Fungal infections are still a relevant challenge for clinicians involved in the cure of patients with cancer. We retrospectively reviewed charts of hospitalized patients with hematological malignancie...

Hematological malignancies presenting as spontaneous tumor lysis syndrome: A case series.

Tumor lysis syndrome is an oncological emergency caused by massive tumor lysis resulting in a constellation of metabolic abnormalities. It is observed most frequently in patients with high-grade hemat...

Autoimmune diseases and hematological malignancies: exploring the underlying mechanisms from epidemiological evidence.

Autoimmune diseases are characterized by the irregular functioning of the immune system that leads to the loss of tolerance to self-antigens. The underlying nature of autoimmune diseases has led to sp...

Medical and Biotech [MESH] Definitions

Use of HIRUDINS as an anticoagulant in the treatment of cardiological and hematological disorders.

A hematopoietic growth factor which promotes proliferation and maturation of neutrophil granulocytes. Clinically it is effective in decreasing the incidence of febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive therapy or in reducing the duration of neutropenia and neutropenia-related clinical sequelae in patients with non-myeloid malignancies undergoing myeloblastive chemotherapy followed by BMT. It has also been used in AIDS patients with CMV retinitis being treated with GANCICLOVIR. (Gelman CR, Rumack BH & Hess AJ (eds): DRUGDEX(R) System. MICROMEDEX, Inc., Englewood, Colorado (Edition expires 11/30/95))

A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.

An alkylating agent of value against both hematologic malignancies and solid tumors.

A condition caused by a brief whole body exposure to more than one sievert dose equivalent of radiation. Acute radiation syndrome is initially characterized by ANOREXIA; NAUSEA; VOMITING; but can progress to hematological, gastrointestinal, neurological, pulmonary, and other major organ dysfunction.

More From BioPortfolio on "A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial